A promising target for breast cancer: B7-H3
Abstract Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a resu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-024-11933-3 |
| _version_ | 1797274273728954368 |
|---|---|
| author | Ying Jiang Jiayu Liu Lingyan Chen Zhiwen Qian Yan Zhang |
| author_facet | Ying Jiang Jiayu Liu Lingyan Chen Zhiwen Qian Yan Zhang |
| author_sort | Ying Jiang |
| collection | DOAJ |
| description | Abstract Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted over the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint. In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC. |
| first_indexed | 2024-03-07T14:56:02Z |
| format | Article |
| id | doaj.art-016dbfdba0e546e1acf466c6b3b3fe47 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-03-07T14:56:02Z |
| publishDate | 2024-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-016dbfdba0e546e1acf466c6b3b3fe472024-03-05T19:22:57ZengBMCBMC Cancer1471-24072024-02-0124111710.1186/s12885-024-11933-3A promising target for breast cancer: B7-H3Ying Jiang0Jiayu Liu1Lingyan Chen2Zhiwen Qian3Yan Zhang4Department of Oncology, Wuxi Maternal and Child Health Care Hospital, Women’s Hospital of Jiangnan University, Jiangnan UniversityDepartment of Oncology, Wuxi Maternal and Child Health Care Hospital, Women’s Hospital of Jiangnan University, Jiangnan UniversityWuxi Maternal and Child Health Hospital, Nanjing Medical UniversityWuxi Maternal and Child Health Hospital, Nanjing Medical UniversityDepartment of Oncology, Wuxi Maternal and Child Health Care Hospital, Women’s Hospital of Jiangnan University, Jiangnan UniversityAbstract Breast cancer (BC) is the second-leading factor of mortality for women globally and is brought on by a variety of genetic and environmental causes. The conventional treatments for this disease have limitations, making it difficult to improve the lifespan of breast cancer patients. As a result, extensive research has been conducted over the past decade to find innovative solutions to these challenges. Targeting of the antitumor immune response through the immunomodulatory checkpoint protein B7 family has revolutionized cancer treatment and led to intermittent patient responses. B7-H3 has recently received attention because of its significant demodulation and its immunomodulatory effects in many cancers. Uncontrolled B7-H3 expression and a bad outlook are strongly associated, according to a substantial body of cancer research. Numerous studies have shown that BC has significant B7-H3 expression, and B7-H3 induces an immune evasion phenotype, consequently enhancing the survival, proliferation, metastasis, and drug resistance of BC cells. Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint. In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.https://doi.org/10.1186/s12885-024-11933-3Breast cancerB7-H3Immune checkpointCancer immunotherapyTumor microenvironmentTargeted immunotherapy |
| spellingShingle | Ying Jiang Jiayu Liu Lingyan Chen Zhiwen Qian Yan Zhang A promising target for breast cancer: B7-H3 BMC Cancer Breast cancer B7-H3 Immune checkpoint Cancer immunotherapy Tumor microenvironment Targeted immunotherapy |
| title | A promising target for breast cancer: B7-H3 |
| title_full | A promising target for breast cancer: B7-H3 |
| title_fullStr | A promising target for breast cancer: B7-H3 |
| title_full_unstemmed | A promising target for breast cancer: B7-H3 |
| title_short | A promising target for breast cancer: B7-H3 |
| title_sort | promising target for breast cancer b7 h3 |
| topic | Breast cancer B7-H3 Immune checkpoint Cancer immunotherapy Tumor microenvironment Targeted immunotherapy |
| url | https://doi.org/10.1186/s12885-024-11933-3 |
| work_keys_str_mv | AT yingjiang apromisingtargetforbreastcancerb7h3 AT jiayuliu apromisingtargetforbreastcancerb7h3 AT lingyanchen apromisingtargetforbreastcancerb7h3 AT zhiwenqian apromisingtargetforbreastcancerb7h3 AT yanzhang apromisingtargetforbreastcancerb7h3 AT yingjiang promisingtargetforbreastcancerb7h3 AT jiayuliu promisingtargetforbreastcancerb7h3 AT lingyanchen promisingtargetforbreastcancerb7h3 AT zhiwenqian promisingtargetforbreastcancerb7h3 AT yanzhang promisingtargetforbreastcancerb7h3 |